export interface Article {
  slug: string;
  title: string;
  tag: string;
  category: "getting-started" | "by-goal" | "deep-dives" | "trust-safety";
  readTime: string;
  excerpt: string;
  content: string;
  relatedProductSlugs: string[];
  relatedArticleSlugs: string[];
}

const DISCLAIMER =
  "DISCLAIMER: This article is provided for informational and educational purposes only. All information is compiled from published peer-reviewed research and is intended solely for qualified laboratory researchers. Nothing in this article constitutes medical, pharmaceutical, therapeutic, diagnostic, or healthcare advice. This article does not recommend, suggest, or endorse the use of any product for human or animal consumption. All products referenced are intended for in-vitro laboratory research use only and are not intended for any diagnostic, therapeutic, or human use. Purity Lab, its owners, employees, and affiliates assume no liability for any actions taken based on the information in this article. Use of any product in a manner inconsistent with its labeled research purpose is strictly prohibited.";

export const articles: Article[] = [
  // ─── Getting Started ───
  {
    slug: "getting-started",
    title: "Introduction to Peptide Chemistry",
    tag: "Fundamentals",
    category: "getting-started",
    readTime: "8 min read",
    excerpt:
      "A foundational overview of peptide chemistry, including molecular structure, classification, and their role in contemporary research applications.",
    content: `Peptides are short chains of amino acids, typically between 2 and 50, linked together by peptide bonds. They occur naturally in every living organism and play essential roles in biological signaling, enzyme regulation, and cellular communication. Research peptides are synthetic versions of these naturally occurring compounds, manufactured to high purity standards for use in laboratory investigation.

The breadth of peptide research continues to expand across multiple scientific disciplines. BPC-157, for instance, has been studied in preclinical models for its role in tissue repair signaling pathways. CJC-1295 and Ipamorelin are investigated for their interaction with growth hormone releasing mechanisms. MOTS-C is the subject of published research examining mitochondrial signaling and metabolic regulation. These represent only a small portion of the active research landscape.

All products sold by Purity Lab are intended strictly for in-vitro laboratory research. They are not approved for human consumption, therapeutic use, or diagnostic purposes. By purchasing research chemicals, the buyer confirms that all materials will be used exclusively in a qualified laboratory setting and handled by trained researchers.

Key terminology used in peptide chemistry includes the following. "Lyophilized" refers to the freeze-drying process used to stabilize peptides as a dry powder for storage and transport. "Reconstitution" describes the process of dissolving lyophilized powder into a solvent such as bacteriostatic water to prepare a solution for laboratory assays. "HPLC" (High-Performance Liquid Chromatography) is the standard analytical method used to determine peptide purity. "Mass Spectrometry" (MS) is used to confirm molecular identity by measuring molecular weight. "mcg" denotes micrograms, the standard unit of measurement for peptide quantities in research.

Proper storage and handling are essential for maintaining compound integrity. Lyophilized peptides are stable at room temperature during transit, but once reconstituted, solutions should be stored at 2-8 degrees Celsius and used within the timeframe specified on the product documentation. All vials should be handled using aseptic technique and stored according to label instructions.

${DISCLAIMER}`,
    relatedProductSlugs: ["bpc-157-5mg", "bac-water-10ml", "syringes"],
    relatedArticleSlugs: ["how-to-reconstitute", "how-to-read-coa"],
  },
  {
    slug: "how-to-reconstitute",
    title: "Laboratory Preparation of Lyophilized Compounds",
    tag: "Lab Methods",
    category: "getting-started",
    readTime: "5 min read",
    excerpt:
      "Standard laboratory procedures for reconstituting lyophilized peptide reference standards, including solvent selection, concentration calculations, and proper storage protocols.",
    content: `Reconstitution is the process of dissolving lyophilized (freeze-dried) peptide powder into a liquid solution so it can be accurately measured and used in laboratory assays. The standard solvent is bacteriostatic water (BAC water), which is sterile water containing 0.9% benzyl alcohol as a preservative. This preservative allows the reconstituted solution to remain stable for up to 30 days under refrigeration, compared to sterile water which contains no preservative and must be used immediately.

Standard laboratory procedure is as follows. Gather the necessary materials: the peptide vial, a vial of bacteriostatic water, appropriate syringes, and alcohol swabs. Swab the rubber stopper of both the peptide vial and the BAC water vial with alcohol and allow them to air dry. Draw the desired volume of BAC water into the syringe. Common volumes are 1 mL or 2 mL, depending on the target concentration for the assay.

Insert the needle into the peptide vial through the rubber stopper. It is critical to avoid directing the solvent stream directly onto the lyophilized powder, as this can disrupt molecular structure. Instead, direct the needle toward the inside wall of the vial and allow the water to flow down gently. Once all solvent has been added, do not agitate the vial. Gently roll the vial between the palms or swirl in small circles until the powder is fully dissolved. This typically requires 1 to 3 minutes. The resulting solution should be clear with no visible particulates.

Concentration calculations are straightforward. For a 5 mg vial reconstituted with 1 mL of solvent, each 0.1 mL contains 500 mcg (0.5 mg). If reconstituted with 2 mL, each 0.1 mL contains 250 mcg. The general formula is: concentration per unit volume = (total peptide mass in mcg) / (total solvent volume in units). For a 10 mg vial reconstituted with 2 mL: 10,000 mcg / 200 units = 50 mcg per unit.

Following reconstitution, store the vial upright under refrigeration at 2-8 degrees Celsius. Do not freeze reconstituted peptide solutions. Use within 28-30 days. Swab the stopper with alcohol before each withdrawal and use a fresh sterile syringe for each aliquot. Discard any solution that becomes cloudy, discolored, or shows particulate matter.

${DISCLAIMER}`,
    relatedProductSlugs: [
      "bac-water-10ml",
      "syringes",
      "bpc-157-5mg",
    ],
    relatedArticleSlugs: ["getting-started", "bpc-157-guide"],
  },
  {
    slug: "how-to-read-coa",
    title: "How to Read a Certificate of Analysis",
    tag: "Trust",
    category: "trust-safety",
    readTime: "4 min read",
    excerpt:
      "Not all CoAs are legitimate. Learn to identify the key fields that separate real third-party testing from manufacturer rubber stamps.",
    content: `A Certificate of Analysis (CoA) is a document issued by an analytical laboratory that confirms the identity and purity of a specific product batch. In the peptide industry, CoAs are your only objective proof of what's actually in a vial. The problem is that not all CoAs are created equal, and some companies exploit this by providing misleading or incomplete documents.

The first thing to check is the testing laboratory's name. A legitimate CoA will clearly identify the independent lab that performed the analysis. If the document just says "tested" without naming the lab, or if the lab name matches the peptide manufacturer, that's a red flag. Independent third-party testing means the lab has no financial incentive to produce favorable results. At Purity Lab, our CoAs name the testing laboratory because we want you to know exactly who verified what's in your vial.

Next, look for HPLC (High-Performance Liquid Chromatography) results. HPLC is the industry standard method for measuring peptide purity. The report should show a specific purity percentage, research-grade peptides should test at 98% or higher. The HPLC chromatogram (the graph showing peaks) should have one dominant peak representing the target peptide and minimal impurity peaks. If a CoA doesn't include HPLC data, it's incomplete at best.

Mass Spectrometry (MS) results confirm molecular identity. The observed molecular weight should match the known molecular weight of the peptide within a narrow margin. This confirms that the substance is actually the peptide it claims to be, not a different compound or a degraded fragment. A CoA with purity data but no identity confirmation is only half the picture.

Always verify that the batch number on the CoA matches the batch number on your product label. A generic CoA without a specific batch reference is essentially worthless, it might represent a completely different production run. Also check the test date. Testing should be recent and specific to your batch. A CoA from two years ago tells you nothing about the product you're holding now.

${DISCLAIMER}`,
    relatedProductSlugs: [],
    relatedArticleSlugs: ["spotting-fake-peptides", "getting-started"],
  },

  // ─── By Goal ───
  {
    slug: "peptides-for-recovery",
    title: "Published Research on BPC-157 and Thymosin Beta-4 in Preclinical Models",
    tag: "Tissue Research",
    category: "by-goal",
    readTime: "7 min read",
    excerpt:
      "A review of published preclinical research on BPC-157 and Thymosin Beta-4, covering their molecular mechanisms, signaling pathways, and findings in tissue repair models.",
    content: `BPC-157 and Thymosin Beta-4 (TB-4) are among the most extensively studied peptides in preclinical tissue research. Both have been the subject of numerous peer-reviewed publications investigating their molecular mechanisms in the context of tissue repair signaling, and they operate through distinct but complementary pathways.

BPC-157 is a pentadecapeptide (a chain of 15 amino acids) originally isolated from human gastric juice. Published research has examined its effects across a range of tissue types, including tendon, ligament, muscle, bone, and gastrointestinal epithelium. Studies in animal models have demonstrated that BPC-157 promotes angiogenesis (the formation of new blood vessels), upregulates growth factor expression (including VEGF), and modulates nitric oxide signaling. Published preclinical studies have specifically examined BPC-157 in models of tendon-to-bone healing, muscle injury, and gastrointestinal lesions.

Thymosin Beta-4 (TB-4) is a naturally occurring 43-amino acid peptide. The primary mechanism studied in published literature involves the upregulation of actin, a protein central to cell migration, wound closure, and neovascularization. Research published in peer-reviewed journals suggests that TB-4 promotes tissue repair through systemic signaling pathways rather than localized effects alone. Studies have examined its role in cell migration, inflammatory modulation, and connective tissue remodeling.

Published literature has also examined the combined effects of BPC-157 and Thymosin Beta-4 in preclinical models. BPC-157 appears to operate through localized signaling pathways while TB-4 acts through broader systemic mechanisms. Together, published studies suggest they may address tissue repair signaling from complementary angles, including angiogenesis, inflammatory modulation, and extracellular matrix remodeling.

It is important to note that the research summarized here is derived from preclinical (animal and in-vitro) models. These findings have not been confirmed in controlled human clinical trials, and no conclusions regarding therapeutic efficacy should be drawn from this summary.

${DISCLAIMER}`,
    relatedProductSlugs: [
      "bpc-157-10mg",
      "tb500-10mg",
      "wolverine-blend-10-10mg",
    ],
    relatedArticleSlugs: ["bpc-157-guide", "getting-started"],
  },
  {
    slug: "peptides-for-fat-loss",
    title: "GLP-1 Receptor Agonists: A Review of Published Research",
    tag: "Metabolic Research",
    category: "by-goal",
    readTime: "6 min read",
    excerpt:
      "A literature review of published research on GLP-1 receptor agonists and related metabolic peptides, including MOTS-C, AOD 9604, and incretin-pathway compounds.",
    content: `Several peptide compounds have been the subject of extensive published research in the field of metabolic signaling and energy regulation. This article summarizes key findings from the peer-reviewed literature on compounds relevant to metabolic pathway research.

MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino acid peptide encoded in the mitochondrial genome. Published research has demonstrated that MOTS-C activates AMPK (adenosine monophosphate-activated protein kinase), a central regulator of cellular energy homeostasis. Studies in animal models have shown that MOTS-C influences insulin sensitivity and fatty acid oxidation pathways. Published findings in preclinical models indicate that MOTS-C administration prevented age-dependent and high-fat-diet-induced insulin resistance. These results have made MOTS-C a compound of significant interest in metabolic and mitochondrial research.

AOD 9604 is a modified fragment of human growth hormone comprising amino acids 177-191. Published research has examined its effects on lipolysis (fat breakdown) and lipogenesis (fat formation) pathways. Studies suggest it interacts with lipid metabolism signaling without affecting blood glucose regulation or growth pathways associated with full-length growth hormone. These properties have made AOD 9604 a subject of interest in lipid metabolism research.

CJC-1295 and Ipamorelin are growth hormone secretagogues that have been studied for their interaction with the GHRH receptor and ghrelin receptor, respectively. Published research has examined the pharmacology of these compounds in the context of growth hormone releasing mechanisms. CJC-1295 has been studied for its effects on sustained GH-axis signaling, while Ipamorelin has been characterized in the literature for its selectivity in stimulating GH release without significantly affecting cortisol or prolactin pathways.

All findings referenced in this article are derived from published preclinical and clinical research. This summary is intended to provide context for laboratory researchers and does not constitute recommendations for any therapeutic application.

${DISCLAIMER}`,
    relatedProductSlugs: [
      "mots-c-40mg",
      "aod-9604-5mg",
      "cjc-ipa-blend-5-5mg",
    ],
    relatedArticleSlugs: [
      "understanding-growth-hormone-secretagogues",
      "getting-started",
    ],
  },

  // ─── Deep Dives ───
  {
    slug: "bpc-157-guide",
    title: "BPC-157: Molecular Biology and Published Research",
    tag: "Deep Dive",
    category: "deep-dives",
    readTime: "10 min read",
    excerpt:
      "A detailed review of the molecular biology of Body Protection Compound-157, including its amino acid sequence, studied mechanisms of action, and key findings from published preclinical research.",
    content: `BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a protein found in human gastric juice and has been the subject of over 100 published research studies since the mid-1990s. Published investigations have examined its molecular interactions in the context of tissue repair signaling, inflammatory modulation, and wound healing pathways.

The primary mechanisms of action described in published literature include promotion of angiogenesis (formation of new blood vessels), upregulation of growth factor expression (including VEGF and EGF), modulation of the nitric oxide (NO) system, and interaction with dopaminergic signaling pathways. Preclinical studies have reported effects on tendon, ligament, muscle, gastrointestinal epithelium, and bone tissue models. Of particular interest in the literature are studies examining BPC-157 in tendon-to-bone healing models and gastrointestinal lesion models.

Published research has also examined BPC-157 in combination with Thymosin Beta-4 (TB-4) in preclinical settings. The literature suggests these two peptides may operate through complementary signaling mechanisms, with BPC-157 acting primarily through localized pathways and TB-4 through broader systemic signaling cascades.

Regarding compound stability: lyophilized (unreconstituted) BPC-157 is stable at room temperature for extended periods, which supports safe transport and storage. Once reconstituted with bacteriostatic water, the solution should be stored under refrigeration at 2-8 degrees Celsius and used within 28-30 days. Reconstituted solutions should not be frozen. The compound should be protected from light and excessive heat. The reconstituted solution should appear clear and colorless; discard any solution that shows cloudiness or particulate matter.

Published safety data from preclinical studies indicate a favorable toxicity profile in animal models. However, it is essential to note that the majority of published BPC-157 research has been conducted in animal and in-vitro models. These findings have not been replicated in controlled human clinical trials, and no conclusions regarding therapeutic safety or efficacy should be drawn from this summary.

${DISCLAIMER}`,
    relatedProductSlugs: [
      "bpc-157-5mg",
      "bpc-157-10mg",
      "bpc-157-20mg",
      "wolverine-blend-10-10mg",
    ],
    relatedArticleSlugs: ["peptides-for-recovery", "how-to-reconstitute"],
  },
  {
    slug: "understanding-growth-hormone-secretagogues",
    title: "Growth Hormone Secretagogues: Receptor Pharmacology and Research",
    tag: "Deep Dive",
    category: "deep-dives",
    readTime: "8 min read",
    excerpt:
      "A review of the receptor pharmacology of growth hormone secretagogues, including CJC-1295 and Ipamorelin, with a focus on GHRH receptor and ghrelin receptor signaling mechanisms.",
    content: `Growth hormone secretagogues (GHS) are a class of peptides studied for their interaction with receptors involved in growth hormone (GH) release from the anterior pituitary. Published research has characterized their receptor pharmacology in detail, distinguishing them from exogenous growth hormone by their mechanism of action through endogenous signaling pathways rather than direct hormone supplementation.

CJC-1295 (without DAC) is a modified analog of Growth Hormone Releasing Hormone (GHRH). It acts as an agonist at the GHRH receptor in the anterior pituitary. Published pharmacokinetic studies have characterized the distinction between CJC-1295 with and without the Drug Affinity Complex (DAC). The variant with DAC exhibits a significantly longer half-life, resulting in sustained receptor activation that alters the endogenous pulsatile release pattern. The variant without DAC has a shorter half-life (approximately 30 minutes), which preserves the native pulsatile signaling pattern and is more commonly referenced in the research literature.

Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor (GHS-R1a) agonist. Published pharmacological studies have characterized its selectivity profile, demonstrating that it stimulates GH release without significantly affecting cortisol, prolactin, or aldosterone levels. This selectivity distinguishes it from earlier ghrelin receptor agonists such as GHRP-6 and GHRP-2, which exhibit broader receptor activity profiles. Published binding studies confirm that Ipamorelin produces GH release pulses consistent with endogenous signaling patterns.

Published research has examined the combination of CJC-1295 and Ipamorelin for potential synergistic receptor interactions. CJC-1295 provides sustained GHRH receptor activation while Ipamorelin produces acute ghrelin receptor stimulation. The combined pharmacological profile has been characterized in the literature as producing a GH elevation pattern that more closely resembles physiological release than either compound alone.

All findings referenced in this article are derived from published preclinical and pharmacological studies. This summary is intended to provide context for laboratory researchers investigating GH-axis signaling and does not constitute recommendations for any therapeutic application.

${DISCLAIMER}`,
    relatedProductSlugs: [
      "cjc-ipa-blend-5-5mg",
      "ipamorelin-10mg",
    ],
    relatedArticleSlugs: ["peptides-for-fat-loss", "peptides-for-recovery"],
  },

  {
    slug: "glp1-peptides-explained",
    title: "GLP-1 Peptides Explained: Semaglutide, Tirzepatide, and Retatrutide",
    tag: "Deep Dive",
    category: "deep-dives",
    readTime: "10 min read",
    excerpt:
      "A comprehensive look at the GLP-1 receptor agonist family, how they differ, what the clinical data shows, and why they dominate metabolic research in 2026.",
    content: `GLP-1 (glucagon-like peptide-1) receptor agonists represent one of the most actively researched classes of peptides in pharmacological science. Originally investigated for glycemic regulation, these compounds have been the subject of extensive published research examining their receptor pharmacology and metabolic signaling mechanisms. Three compounds are prominent in the current literature: Semaglutide, Tirzepatide, and Retatrutide. Each represents a different approach to incretin receptor targeting.

Semaglutide is a selective GLP-1 receptor agonist. Published research has characterized its mechanism of action through central nervous system signaling pathways, gastric motility modulation, and insulin sensitivity pathways. The STEP clinical trial program generated extensive published data on Semaglutide's pharmacological profile, with Phase 3 and Phase 4 studies enrolling thousands of subjects. Semaglutide has FDA approval for specific indications, giving it the most extensive regulatory and clinical evidence base of any compound in this class.

Tirzepatide is a dual GLP-1/GIP (glucose-dependent insulinotropic polypeptide) receptor agonist that activates two incretin pathways simultaneously. The SURMOUNT clinical trial program produced published data demonstrating that dual-receptor activation produces distinct pharmacological effects compared to single-receptor targeting. The GIP receptor component enhances insulin secretion in a glucose-dependent manner and appears to amplify the metabolic signaling response beyond what GLP-1 receptor activation achieves independently. Tirzepatide also has FDA approval for specific indications.

Retatrutide represents a triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 clinical trial data have been published examining its pharmacological profile. The glucagon receptor activation is the key differentiator from dual-receptor compounds. While GLP-1 and GIP receptor activation address incretin signaling, glucagon receptor activation engages energy expenditure and lipid oxidation pathways directly. Retatrutide is currently in clinical development and does not yet have regulatory approval.

For researchers, the progression from single to dual to triple-receptor targeting illustrates an important principle in peptide pharmacology: multi-receptor engagement can produce pharmacological effects that differ qualitatively from single-target activation. The metabolic signaling network is interconnected, and compounds that engage multiple receptor nodes simultaneously are an active area of investigation. All findings referenced here are from published clinical and preclinical research.

${DISCLAIMER}`,
    relatedProductSlugs: [
      "semaglutide",
      "tirzepatide",
      "retatrutide-glp3",
      "cagrilintide",
    ],
    relatedArticleSlugs: ["peptides-for-fat-loss", "getting-started"],
  },
  {
    slug: "mitochondrial-peptides",
    title: "Mitochondrial Peptides: MOTS-C, SS-31, and the Future of Cellular Energy Research",
    tag: "Deep Dive",
    category: "deep-dives",
    readTime: "8 min read",
    excerpt:
      "How mitochondrial-targeted peptides work, what separates MOTS-C from SS-31, and why cellular energy research is one of the fastest-growing areas in peptide science.",
    content: `Mitochondria are the primary sites of ATP production in eukaryotic cells. Declining mitochondrial function has been associated in published research with reduced ATP output, increased oxidative stress, and disrupted metabolic signaling. Mitochondrial-targeted peptides represent an active area of research because they interact with cellular energy production pathways at the organelle level.

MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino acid peptide encoded directly in the mitochondrial genome. This is significant because MOTS-C is produced by mitochondria as an endogenous signaling molecule. Published research has demonstrated that MOTS-C activates AMPK (adenosine monophosphate-activated protein kinase), a central regulator of cellular energy homeostasis that influences glucose uptake, fatty acid oxidation, and insulin signaling pathways. In published animal studies, MOTS-C administration prevented both age-dependent and high-fat-diet-induced insulin resistance. Published findings also describe effects on exercise capacity models and metabolic homeostasis under stress conditions. MOTS-C levels have been shown to decline with age in published studies, making it a compound of significant interest in metabolic and aging research.

SS-31 (Elamipretide) operates through a fundamentally different mechanism. Rather than functioning as a metabolic signaling molecule, SS-31 is a synthetic tetrapeptide that physically targets the inner mitochondrial membrane. Published research has shown it concentrates within mitochondria at levels 1,000 to 5,000 times higher than in the extracellular space, where it interacts with cardiolipin. Cardiolipin is a phospholipid essential for the structural integrity of the electron transport chain and efficient ATP synthesis. Published studies describe how oxidative damage to cardiolipin reduces electron transport chain efficiency, leading to decreased ATP production and increased reactive oxygen species generation. SS-31 has been studied for its ability to stabilize cardiolipin interactions and support electron transport chain function. Published clinical trials have investigated SS-31 in the context of heart failure, Barth syndrome, age-related mitochondrial dysfunction, and skeletal muscle bioenergetics.

The two compounds address different aspects of mitochondrial biology. MOTS-C operates as a broad metabolic signaling molecule at the systemic level, while SS-31 functions at the mitochondrial membrane to support the core machinery of ATP production. Researchers investigating mitochondrial biology may find value in studying both compounds, as they illuminate distinct facets of mitochondrial function.

Other compounds in the mitochondrial research space include NAD+ precursors (which support mitochondrial enzyme cofactor availability) and Epitalon (which has been studied in published research for effects on cellular aging markers including telomere maintenance). The convergence of these research areas reflects a growing body of literature connecting cellular energy production to metabolic regulation and aging. For laboratory researchers, mitochondrial peptides provide molecular tools for investigating these signaling pathways.

${DISCLAIMER}`,
    relatedProductSlugs: [
      "mots-c-10mg",
      "ss-31-elamipretide",
      "nad-500mg",
      "epitalon",
    ],
    relatedArticleSlugs: [
      "peptides-for-fat-loss",
      "understanding-growth-hormone-secretagogues",
    ],
  },

  // ─── Trust & Safety ───
  {
    slug: "spotting-fake-peptides",
    title: "How to Spot Fake or Underdosed Peptides",
    tag: "Trust",
    category: "trust-safety",
    readTime: "5 min read",
    excerpt:
      "Key indicators of low-quality, underdosed, or counterfeit research chemicals, and quality verification methods for laboratory procurement.",
    content: `The research peptide market has a quality problem. Because peptides are sold for research use and aren't regulated like pharmaceuticals, the barrier to entry for suppliers is low. This means the market includes everything from pharmaceutical-grade manufacturers to operations rebottling underdosed or entirely different compounds. Knowing what to look for can save you from wasting money on products that don't contain what the label claims.

Price is a data point, not a verdict. If a company is selling BPC-157 5mg for $15 when the market average is $40-60, that should raise questions. Peptide synthesis has real costs, raw materials, purification, quality control, and testing. Prices significantly below market average often mean corners were cut somewhere, and that somewhere is usually purity or accurate dosing. That said, the most expensive option isn't automatically the best either. Look at the whole picture: pricing, testing transparency, and company reputation.

The single most important quality indicator is third-party testing. Check whether the company publishes Certificates of Analysis from an independent lab (not the manufacturer). The CoA should name the testing laboratory, show HPLC purity results (98%+ for research grade), include Mass Spectrometry identity confirmation, and reference a specific batch number. If a company can't or won't provide this, that tells you everything. At Purity Lab, we publish every CoA on our website and link them to specific batch numbers so you can verify exactly what's in your vial.

Visual inspection of the lyophilized powder offers additional clues, though it's not definitive. Research-grade peptides typically appear as a white to off-white dry powder or puck at the bottom of the vial. If the powder is yellow, brown, or has an unusual consistency, that could indicate degradation or contamination. After reconstitution, the solution should be clear and colorless. Cloudiness, discoloration, or floating particles are red flags. However, visual inspection alone can't confirm purity, that requires analytical testing.

Source transparency matters. Reputable peptide companies will tell you where their products are synthesized, where they're tested, and how they're handled throughout the supply chain. Vague claims like "pharmaceutical grade" or "99% purity" without supporting documentation are marketing, not evidence. Look for companies that publish their testing methodology, name their testing partners, and provide batch-specific (not generic) Certificates of Analysis.

${DISCLAIMER}`,
    relatedProductSlugs: [],
    relatedArticleSlugs: ["how-to-read-coa", "getting-started"],
  },
];

export const CATEGORY_LABELS: Record<string, string> = {
  "getting-started": "Getting Started",
  "by-goal": "Research Reviews",
  "deep-dives": "Deep Dives",
  "trust-safety": "Trust & Safety",
};

export const CATEGORY_ORDER = [
  "getting-started",
  "by-goal",
  "deep-dives",
  "trust-safety",
];

export function getArticleBySlug(slug: string): Article | undefined {
  return articles.find((a) => a.slug === slug);
}

export function getArticlesByCategory(
  category: string
): Article[] {
  return articles.filter((a) => a.category === category);
}
